The 2022 Goldman Prize is awarded to Professor Andreas Hochhaus

We are delighted to announce Professor Andreas Hochhaus, Head of the Department of Hematology and Medical Oncology at Jena University Hospital as the 2022 Goldman Prize recipient. He receives the prize in recognition of his outstanding clinical leadership in CML and for his lifelong contributions to the optimization of CML therapy – through his work on mechanisms of resistance and stem cell persistence, through leading clinical studies and through the development of clinical recommendations. The annual Goldman Prize awarded in honour of Professor John Goldman, acknowledges outstanding lifetime contributions to the management of patients with CML.

Through his research over the past decades, Andreas Hochhaus has made a significant contribution to optimizing the treatment of patients with chronic myeloid leukemia and myeloproliferative neoplasm. In the 1990’s he was actively involved in pioneering measurable residual disease in patients treated with interferon. Later, he has led groundbreaking research on the mechanisms of resistance (e.g. his landmark plenary talk on BCR::ABL1 mutations at ASH 2001) and mechanisms of stem cell persistence.

Andreas Hochhaus contributed largely to the clinical development of imatinib and next generation TKI’s. He was investigator or co-investigator of many of the vital phase I, II, III and IV trials and was particularly involved in the evolution of combination therapies. He has been involved in the management of randomized CML studies of the German CML Study Group for more than 30 years and is lead investigator of the TIGER trial (2012-2022). Since 2016, he has also been coordinating the EUTOS for CML group. Recently, he dedicated his research on the clinical development of asciminib and translational research in CML and other cancers.

Professor Hochhaus’ expertise has found its way into numerous clinical guidelines and he is lead author of the European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

As Co-chair of the German CML Alliance, Professor Hochhaus is also focused on enhancing access to clinical trials for all patients and in driving patient participation. Over the years, he has worked closely with patient advocacy groups and has participated as an expert at the annual ‘CML Horizon’ conferences organized by the CML Advocates Network.

Andreas Hochhaus is Director of the Department of Hematology and Medical Oncology and Coordinator of the University Tumor Center at Jena University Hospital in Germany. He is full professor for Internal Medicine / Hematology and Oncology at the Friedrich-Schiller-University, Jena, Germany and served as Vice Dean for Research at the Medical Faculty from 2010 – 2020.

Before taking over his current position, he was Head of the Department of Leukemia Research at the Medical Faculty Mannheim, Heidelberg University and was awarded the Endowed Professorship for Leukemia Research from the German José Carreras Leukemia Foundation in 2007. He studied medicine at the University of Leipzig and the Medizinische Akademie Erfurt.

He completed his postgraduate studies and doctoral degree (Dr. med) at the University of Erfurt and received a postgraduate scholarship from the Hammersmith Hospital in London.
He habilitated in Internal Medicine at the University of Heidelberg and was appointed as full (W3) Professor in 2007.

Andreas Hochhaus has published 617 peer-reviewed papers and is Co-Editor-in-Chief of Leukemia.

Learn more about Professor Hochhaus work here